TEVA-OXYBUTYNIN TABLET
Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Charakteristika produktu
(SPC)
21-09-2021
Některé dokumenty pro tento produkt momentálně nejsou k dispozici, můžete poslat požadavek našemu zákaznickému servisu a my vás upozorníme, jakmile je dokážeme získat.
Poslat žádost.
Poslat žádost.
Aktivní složka:
OXYBUTYNIN CHLORIDE
Dostupné s:
TEVA CANADA LIMITED
ATC kód:
G04BD04
INN (Mezinárodní Name):
OXYBUTYNIN
Dávkování:
5MG
Léková forma:
TABLET
Složení:
OXYBUTYNIN CHLORIDE 5MG
Podání:
ORAL
Jednotky v balení:
100/500/1000
Druh předpisu:
Prescription
Terapeutické oblasti:
Antimuscarinics
Přehled produktů:
Active ingredient group (AIG) number: 0114692001; AHFS:
Stav Autorizace:
APPROVED
Datum autorizace:
2014-06-12
Charakteristika produktu
PRODUCT MONOGRAPH
PR
TEVA-OXYBUTYNIN
oxybutynin
chloride tablets, USP, 5 mg
Anticholinergic/Antispasmodic Agent
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Date of Revision:
September 21, 2021
Submission Control No: 251700
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
...................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................3
CONTRAINDICATIONS
.............................................................................................4
WARNINGS AND PRECAUTIONS
.............................................................................4
ADVERSE REACTIONS
..............................................................................................6
DRUG INTERACTIONS
..............................................................................................8
DOSAGE AND ADMINISTRATION
...........................................................................9
OVERDOSAGE
............................................................................................................9
STORAGE AND STABILITY
....................................................................................
12
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................ 12
PART II: SCIENTIFIC INFORMATION
...........................................................................
13
PHARMACEUTICAL INFORMATION
....................................................................
13
CLINICAL TRIALS
...................................................................................................
14
DETAILED PHARMACOLOGY
...............................................................................
14
TOXICOLOGY...........................................................................................................
15
REFERENCES
........................................................
Přečtěte si celý dokument
